Nguyen Bui Tam Chi

Ms. Nguyen Bui Tam Chi

Global Education and Medical Sciences, Osaka Metropolitan University, Ōsaka, Japan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
LTLe Thi Thanh Thuy
Le Thi Thanh Thuy
HHHoang Hai
Hoang Hai
APAnh Tuan Pham
Anh Tuan Pham
Nguyen Bui Tam ChiNguyen Bui Tam Chi
Nguyen Bui Tam Chi
BTBao Van Tran
Bao Van Tran
MHMichelle Hermiston
Michelle Hermiston
Chronic liver diseases, including fibrosis and hepatocellular carcinoma (HCC), are primarily driven by oxidative stress, yet traditional antioxidant therapies often lack the specificity and efficacy required for clinical success. This review evaluates the emerging therapeutic potential of two atypical globins, cytoglobin (CYGB) and neuroglobin (NGB), exploring their unique hexacoordinated heme structures that enable potent reactive oxygen and nitrogen species (ROS/RNS) scavenging and redox-regulated signaling. We summarize a broad range of in vitro and in vivo evidence demonstrating that these globins deactivate hepatic stellate cells, reduce extracellular matrix accumulation, and function as tumor suppressors by modulating pathways such as Raf/MEK/ERK and NRF2. In human cohorts, CYGB expression levels inversely correlate with the progression of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and HCC, highlighting its potential as a clinical biomarker. Furthermore, recombinant protein therapies involving CYGB and NGB show promise in promoting collagen degradation and inhibiting malignant transformation. We conclude that CYGB and NGB represent sophisticated catalytic redox regulators that offer a novel therapeutic paradigm for restoring redox homeostasis. While delivery and pharmacokinetic barriers remain, these globins are highly promising candidates for first-in-class biologics in hepatology.

12 March 2026
Verified
Book Chapter
Open access
PDF file
LTLe Thi Thanh Thuy
Le Thi Thanh Thuy
HHHoang Hai
Hoang Hai
APAnh Tuan Pham
Anh Tuan Pham
Nguyen Bui Tam ChiNguyen Bui Tam Chi
Nguyen Bui Tam Chi
PDPham Minh Duc
Pham Minh Duc
MHMichelle Hermiston
Michelle Hermiston
Reactive oxygen species (ROS) play a pivotal role in the pathogenesis and progression of liver cancer, particularly hepatocellular carcinoma (HCC). While physiological levels of ROS are essential for cellular signaling, excessive ROS generation leads to oxidative stress, DNA damage, lipid peroxidation, and chronic inflammation – all of which contribute to malignant transformation and tumor promotion. This chapter explores the dual nature of ROS in liver physiology and tumorigenesis, highlighting their involvement in hepatocyte injury, fibrosis, and activation of pro-oncogenic pathways such as NF-κB, STAT3, and PI3K/AKT. We also discuss how antioxidant agents, including cytoglobin and neuroglobin, regulate ROS levels to protect the liver from fibrosis and cancer progression. Understanding the mechanisms by which ROS promote liver cancer can inform novel therapeutic strategies targeting redox homeostasis and oxidative stress responses in HCC.

23 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NSNguyen Tran Quang Sang
Nguyen Tran Quang Sang
NKNguyen Van Khanh
Nguyen Van Khanh
HHHoang Hai
Hoang Hai
DTDung Trung Tran
Dung Trung Tran
Tran Duc ThanhTran Duc Thanh
Tran Duc Thanh
LTLe Thi Thanh Thuy
Le Thi Thanh Thuy
Background: Osteosarcoma remains the most common primary malignant bone tumor in children and adolescents, with largely unchanged survival outcomes in recent decades. Non-invasive biomarkers for preoperative risk stratification are urgently needed. Circulating immune checkpoint proteins (ICPs) and bone remodeling factors (BRFs) represent promising candidates; however, their combined prognostic value in osteosarcoma remains unclear. Methods: We prospectively analyzed plasma samples from 47 patients with osteosarcoma, selecting the earliest available sample before disease progression or the last follow-up. A panel of ICPs and BRFs was quantified using multiplex immunoassays. sHVEM and sCD27 were used to construct a two-marker ICP signature (ICP2); subtypes were defined by unsupervised consensus clustering (k = 2) applied to log2-transformed sHVEM and sCD27 concentrations, and sOPN was included for integrative analysis. Survival associations were assessed using Kaplan–Meier analysis and Firth’s penalized Cox regression. The model performance was evaluated using Harrell’s C-index. Results: Two ICP2 subtypes were identified (type1, n = 26; type2, n = 21). ICP2-type2 was associated with significantly worse progression free survival (PFS) (p = 0.0045) and overall survival (OS) (p = 0.0024) and remained an independent predictor after adjusting clinicopathological factors. The ICP2 model demonstrated high discriminative performance (C-index 0.924 for PFS and 0.903 for OS). Internal validation by leave-one-out cross-validation (LOOCV), in which consensus clustering was re-derived at each fold, yielded corrected C-indices of 0.612 for PFS and 0.806 for OS (versus apparent estimates of 0.687 and 0.689, respectively), confirming acceptable-to-good discrimination after accounting for overfitting. Elevated sOPN was associated with poorer survival in the exploratory analyses, although its prognostic value was less consistent under a pre-specified cutoff. In the combined models, sOPN provided modest additional value for OS stratification, with the grdgfdgICP2-type2/OPN-high subgroup exhibiting the poorest outcome. Conclusions: The circulating sHVEM/sCD27 signature defines prognostically distinct osteosarcoma subtypes with a strong discriminative performance. This minimally invasive model may support preoperative risk stratification. Integration with sOPN suggests a potential biological link between immune regulation and bone remodeling, warranting validation in larger cohorts.

26 June 2026 in Journal of Bone Oncology
Verified
Journal Article
Open access
NKNguyen Van Khanh
Nguyen Van Khanh
TDTran Trung Dung
Tran Trung Dung
HHHoang Hai
Hoang Hai
NSNguyen Tran Quang Sang
Nguyen Tran Quang Sang
TTTran Duc Thanh
Tran Duc Thanh
LTLe Thi Thanh Thuy
Le Thi Thanh Thuy
Osteosarcoma (OS) suffers from stagnant survival rates due to high metastatic potential and genomic complexity. Here, we present a high-resolution single-cell transcriptomic atlas of the OS ecosystem using single-cell fixed RNA profiling (FLEX) of 40,401 cells across four clinical stages: treatment-naïve, post-chemotherapy, recurrent, and lung metastatic. We identified a metastasis-enriched malignant subpopulation, OB_3, characterized by aggressive transcriptional signatures and governed by ADAMTS12, which we validated as a prognostic marker for reduced overall survival. Functional in vitro experiments further demonstrated that ADAMTS12 silencing significantly reduced the migratory capacity of HOS and 143B OS cells and suppressed AKT and ERK phosphorylation, thereby supporting its role as an active driver of metastatic progression. Within the microenvironment, metastatic progression was defined by the emergence of RNASE1+ M2-like tumor-associated macrophages, an expansion of highly immunosuppressive S100A4+ regulatory T cells, and the specialization of PLVAP+ stalk endothelial cells driving tumor angiogenesis. Integrative interactome analysis revealed that these populations function as central coordinating hubs, utilizing MIF, SPP1, and Galectin signaling to orchestrate the metastatic niche. Our findings, validated across multiple external cohorts and tissue microarrays, delineate a coordinated multi-cellular network involving ADAMTS12+, RNASE1+, S100A4+, and PLVAP+ cells. This study clarifies how malignant and microenvironmental components co-evolve to facilitate systemic dissemination, providing a translational framework for precision risk stratification and the development of next-generation therapeutic strategies to counteract metastatic OS.